NLM Logo

pimavanserin MeSH Supplementary Concept Data 2022


MeSH Supplementary
pimavanserin
Unique ID
C510793
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C510793
Entry Term(s)
ACP 103
ACP-103
ACP103
N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide
Nuplazid
bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate
pimavanserin tartrate
urea, n-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)
Pharm Action
Antiparkinson Agents
Antipsychotic Agents
Serotonin 5-HT2 Receptor Antagonists
Registry Number
JZ963P0DIK
Related Numbers
NA83F1SJSR
Heading Mapped to
*Piperidines
Urea / *analogs & derivatives
Frequency
154
Note
A 5-HT(2A) inverse agonist; ACP-103 is the dihydroxybutanedioate (2:1) salt. It is used to treat hallucinations and delusions associated with PARKINSON DISEASE; structure in first source.
Source
J Pharmacol Exp Ther 2006 May;317(2):910-8
Date of Entry
2006/06/07
Revision Date
2018/11/15
pimavanserin Preferred
ACP 103 Narrower
Nuplazid Narrower
pimavanserin tartrate Narrower
page delivered in 0.005s